Neurogene Inc.
For the period ended Dec 31, 2024. Filed Mar 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 24, 2025
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current Assets: | ||
| Cash and cash equivalents | $136,586 | $148,210 |
| Short-term investments | 175,819 | 48,947 |
| Prepaid expenses and other current assets | 3,518 | 3,191 |
| Total current assets | 315,923 | 200,348 |
| Property and equipment, net | 15,422 | 17,174 |
| Operating lease right-of-use assets | 3,000 | 3,681 |
| Finance lease right-of-use assets | 71 | 98 |
| Restricted cash | 339 | 508 |
| Other non-current assets | 975 | 764 |
| Total assets | $335,730 | $222,573 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,336 | $2,596 |
| Accrued expenses and other current liabilities | 9,731 | 17,495 |
| Operating lease liabilities, current | 2,945 | 2,559 |
| Finance lease liabilities, current | 54 | 42 |
| Contingent value rights liability, current | 1,091 | 281 |
| Total current liabilities | 15,157 | 22,973 |
| Operating lease liabilities, non-current | 9,403 | 12,302 |
| Finance lease liabilities, non-current | 26 | 65 |
| Contingent value rights liability, non-current | 718 | 1,006 |
| Other liabilities | 51 | 203 |
| Total liabilities | 25,355 | 36,549 |
| Stockholders' equity | ||
| Preferred stock, 0.000001 par value; 50,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.000001 par value; 450,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 14,854,725 and 12,823,665 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | — | — |
| Additional paid-in capital | 572,673 | 373,178 |
| Accumulated deficit | (262,298) | (187,154) |
| Total stockholders' equity | 310,375 | 186,024 |
| Total liabilities and stockholders' equity | $335,730 | $222,573 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.